Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

Phase 4

• Conditions: Constipated Irritable Bowel Syndrome; Chronic Constipation; Healthy
• Interventions: Drug: Mosapride

• Registration Number: NCT02433847
• Lead Sponsor: Seoul National University Hospital

Brief Summary

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

Detailed Description

Not available

Study Timeline

• Status Verified: 2015-04
• Study First Submitted: 2015-04-13
• Study First Submitted QC: 2015-04-29
• Last Update Submitted: 2015-04-29
• Study Start: 2015-05
• Study First Posted: 2015-05-05
• Last Update Posted: 2015-05-05
• Primary Completion: 2016-04
• Study Completion: 2016-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria

Exclusion Criteria

• Intolerable or hypersensitive to mosapride
• Known Parkinson's ds
• Cardio- or cerebrovascular disease within 3 months
• Malignancy requiring surgery or chemotherapy or radiation within 5 years
• History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation
• Refractory diabetes mellitus/hypertension/thyroid diseases
• Symptomatic heart failure, renal failure, arrhythmia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
mosapride	Mosapride	-

Primary Outcome Measures

Name	Time	Method
colonic transit time	2 weeks	the change of colonic transit time after mosapride 30mg/day administration; : whole colonic transit time, rt. colon / lt. colon / rectosigmoid colonic transit time